Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders

Becton, Dickinson (BD) has completed the acquisition of C.R. Bard, creating a new healthcare company with approximately $16 billion in annualized revenue. Vincent A Forlenza, chairman and CEO, said the combined company builds on BD’s position in medication management and infection prevention with an expanded offering of solutions across the care